CT Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

CT Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$25.9K	Hold	295	–	–	0.02%	331
2016 Q4	$24.4K	Hold	295	–	–	0.02%	334
2016 Q3	$27.3K	Hold	295	–	–	0.02%	323
2016 Q2	$23K	Sell	295 -300	-50%	-$25.5K	0.01%	336
2016 Q1	$49.1K	Hold	595	–	–	0.03%	292
2015 Q4	$62.3K	Hold	595	–	–	0.04%	269
2015 Q3	$62.7K	Hold	595	–	–	0.04%	264
2015 Q2	$81.4K	Buy	595 +545	+1,090%	+$67.5K	0.05%	246
2015 Q1	$6.23K	Buy	+50	New	+$5.3K	﹤0.01%	505
2014 Q1	$6.23K	Buy	+50	New	+$3.69K	﹤0.01%	505

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CT Financial Advisors's BMRN Position: Q1 2017 in Review

CT Financial Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2017 at 295 shares worth $25.9K. The position accounts for 0.02% of the portfolio, ranked #331.

CT Financial Advisors first reported a position in BMRN in Q1 2014 and has held it in 10 quarters since. The position peaked at $81.4K in Q2 2015. 418 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

CT Financial Advisors held 295 shares of BioMarin Pharmaceuticals worth $25.9K as of Q1 2017.
CT Financial Advisors left its BioMarin Pharmaceuticals share count unchanged in Q1 2017.
BioMarin Pharmaceuticals made up 0.02% of CT Financial Advisors's portfolio in Q1 2017, its #331 holding.
CT Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 10 quarters since.
CT Financial Advisors's BioMarin Pharmaceuticals position peaked at $81.4K in Q2 2015.
418 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.